Key facts
- This page summarizes Douglas E. Williams's Form 4 filing for Sana Biotechnology, Inc. (SANA).
- 2 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 08 Mar 2024, 16:18.
Douglas E. Williams - 07 Mar 2024 Form 4 Insider Report for Sana Biotechnology, Inc. (SANA)
- Reporting relationship
- EVP & President, R&D
- Issuer ticker
- SANA
- Reported as of
- 07 Mar 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 08 Mar 2024, 16:18:38 UTC
- Prior SEC filing
- 03 Nov 2023
- Next SEC filing
- 12 Nov 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Julie Shah, Attorney-in-Fact for Douglas E. Williams
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Douglas E. Williams filed Form 4 for Sana Biotechnology, Inc. (SANA) on 08 Mar 2024.
Change
- Previous filing in this sequence was filed on 03 Nov 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
SANA
transaction
Derivative
Restricted Stock Units
Award
- Transaction value
- $0
- Shares
- +67,083
- Change %
- Price
- $0.000000
- Shares after
- 67,083
- Date
- 07 Mar 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 67,083
- Exercise price
- Footnotes
- F1, F2
SANA
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +301,875
- Change %
- Price
- $0.000000
- Shares after
- 301,875
- Date
- 07 Mar 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 301,875
- Exercise price
- $9.58
- Footnotes
- F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
Each restricted stock unit represents a contingent right to receive one share of Sana Biotechnology, Inc. ("Sana") common stock.
Footnote F2
The restricted stock units vest in four equal installments on each of March 7, 2025, 2026, 2027 and 2028, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date.
Footnote F3
The option vests and becomes exercisable as to 25% of the underlying shares on March 7, 2025 and in 36 equal monthly installments thereafter, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date.